Enlivex Ltd. ENLV

Company Overview

Enlivex Ltd. is a clinical-stage biotechnology company focused on developing macrophage reprogramming immunotherapies for inflammatory and infectious diseases. The company operates within the biotechnology and immunotherapy industries and is primarily engaged in research and development activities rather than commercial product sales. Its lead product candidate, Allocetra™, is designed to reprogram macrophages into their homeostatic state in order to address life-threatening immune dysregulation associated with conditions such as sepsis, solid tumors, and complications related to organ dysfunction and hyperinflammation. The company’s revenue profile has historically consisted primarily of research-related grants, financial income, and capital raising activities, as it has not yet commercialized approved therapies.

Enlivex was founded in Israel and became publicly traded on the Nasdaq Capital Market under the ticker ENLV. The company evolved from early-stage immunology research centered on apoptotic-cell-based therapies and expanded its clinical focus into severe inflammatory conditions with high unmet medical need. Its strategic positioning is based on a differentiated immunomodulatory platform intended to regulate macrophage activity broadly rather than targeting a single inflammatory cytokine pathway. Public filings and company disclosures indicate that the company’s development strategy centers on indications where immune overactivation contributes significantly to morbidity and mortality.

Business Operations

Enlivex operates primarily as a single biotechnology development business focused on advancing its proprietary Allocetra™ platform through preclinical and clinical development. The company’s activities include conducting clinical trials, regulatory engagement, manufacturing process development, intellectual property management, and scientific collaboration initiatives. Operations are concentrated largely in Israel, with additional clinical and investor-facing activities conducted in the United States. As a development-stage biotechnology company, Enlivex generates limited operating revenue and finances operations mainly through equity offerings, warrants, and other financing arrangements disclosed in SEC filings.

The company controls proprietary immunotherapy technology related to apoptotic-cell-mediated macrophage reprogramming and maintains intellectual property protections associated with its therapeutic platform. Enlivex has collaborated with hospitals, research institutions, and clinical centers involved in studies relating to sepsis and immune-mediated diseases. Public disclosures identify no large-scale commercial subsidiaries or diversified operating divisions, reflecting its current status as a focused clinical-stage biotechnology enterprise. Data regarding extensive joint ventures or material international operating subsidiaries remains limited in publicly available filings.

Strategic Position & Investments

Enlivex’s strategic direction centers on advancing Allocetra™ through clinical development in severe inflammatory and immune-mediated conditions, particularly sepsis and related systemic inflammatory disorders. The company has emphasized expanding clinical evidence supporting macrophage reprogramming as a therapeutic mechanism capable of restoring immune balance. Growth initiatives have included progressing clinical trials, strengthening manufacturing capabilities for cell-based therapies, pursuing regulatory engagement in multiple jurisdictions, and evaluating additional therapeutic indications where immune dysregulation is central to disease progression.

The company has also explored broader applications of its technology platform in oncology and infectious disease settings. Public disclosures indicate continued investment in research and development infrastructure and intellectual property expansion rather than large-scale acquisitions. Enlivex’s strategic emphasis reflects the broader biotechnology industry trend toward immunomodulatory therapeutics and precision immune intervention. Available public information does not indicate material acquisitions or a broad portfolio of operating subsidiaries. Data inconclusive based on available public sources regarding significant minority investments or extensive portfolio holdings.

Geographic Footprint

Enlivex is headquartered in Ness Ziona, Israel, and maintains operational activities tied primarily to clinical development and biotechnology research. The company is publicly listed in the United States through the Nasdaq Capital Market, providing access to U.S. capital markets and institutional investors. Clinical collaborations and regulatory interactions have involved both Israeli and international medical institutions, supporting broader development and trial execution activities.

The company’s operational presence is concentrated mainly in Israel and the United States, though its strategic ambitions target broader global pharmaceutical and biotechnology markets. Enlivex’s therapies are intended for diseases with worldwide clinical relevance, particularly sepsis and inflammatory disorders that affect healthcare systems globally. Publicly available information does not indicate significant commercial infrastructure across Europe, Asia-Pacific, or Latin America, reflecting the company’s current development-stage profile.

Leadership & Governance

Enlivex is led by an executive team with backgrounds in biotechnology, pharmaceuticals, finance, and clinical development. Leadership has consistently emphasized advancing the company’s macrophage reprogramming platform through disciplined clinical execution, scientific validation, and regulatory engagement. Corporate governance is overseen by a board of directors and management team responsible for clinical strategy, financing activities, and operational oversight as disclosed in company reports and SEC filings.

Key executives and leadership figures include:

• Oren Hershkovitz – Chief Executive Officer
• Nissim Darvish, Ph.D. – Executive Chairman
• Shirly Pinto – Chief Financial Officer
• Dror Mevorach, M.D. – Founder and Scientific Founder

The company’s leadership strategy has focused on advancing clinical-stage assets while preserving financial flexibility and building scientific credibility in the immunotherapy sector. Public company disclosures consistently emphasize evidence-driven development and expansion of clinical data supporting the therapeutic potential of macrophage homeostasis restoration.